# A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

Source: https://onco.cc/trials/nct07227597/  
OnCo record `nct07227597` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Ifinatamab deruxtecan, Atezolizumab, Carboplatin in small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) is a phase 1/2 interventional study registered as NCT07227597 by Merck Sharp & Dohme LLC, with 170 participants planned, started 2026-01-29 and due to reach its primary completion in 2030-11-29. Interventions recorded: Gocatamig, I-DXd, Atezolizumab, Carboplatin, Etoposide. Conditions listed: Small Cell Lung Cancer Extensive Stage. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07227597
- Phase: 1/2
- Setting: A Phase 1b/2 Open-label Study Evaluating Different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-Based Regimens in First-line Extensive Stage Small Cell Lung Cancer
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 170

## Sources

- ClinicalTrials.gov NCT07227597: https://clinicaltrials.gov/study/NCT07227597

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Etoposide](https://onco.cc/drugs/etoposide/), [Ifinatamab deruxtecan](https://onco.cc/drugs/ifinatamab-deruxtecan/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct07227597.json